Topical delivery of interleukin‐13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis

Abstract

These data suggests that IL-13 ASO/cEL complex can provide a potential therapeutic tool for the treatment of AD and also be applied to other immune diseases associated with the production of Il-13.

Strategies targeting the IL-4/IL-13 axes in disease

“…IL-13 antisense liposomes decreased skin thickness, reduced skin biopsy IL-4 and IL-5 and skin inflammation and reduced serum IgE in comparison to naked liposomes [207]. IL-4 and IL-13 were neutralized in a mouse ear model of repeated oxazolone ear exposure, which drives an AD like phenotype, using systemic exposure to a plasmid coding for an IL-4 double mutant after sensitization had developed (IL-4DM; blocks both IL-4 and IL-13 by competing for binding at IL-4Ra).…”

Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges

“…Enhanced expression of IL-4 led to suppressed hyperplastic and inflamed vessels in the skin. Similarly, Kim et al used liposomes complexed with antisense ODN for IL-13 mRNA to treat atopic dermatitis in vivo [36]. Treatment with liposome formulation resulted in a significant reduction in skin thickness and inflammatory cell infiltration.…”

Bioanalysis of siRNA and Oligonucleotide Therapeutics in Biological Fluids and Tissues

“…Is a ligand-binding assay used for the determination of the oligonucleotide therapeutic future science group Administration & PK Oligonucleotides have been administered by various routes in support of preclinical and clinical studies, including ocular [50], parenteral intravenous injection [35], intravenous infusion [51], topical [52], subcutaneous injection [53], intramuscular injection [54], lung inhalation [55], intranasal inhalation [56], intracerebral [57] and even oral routes [58]. The choice of drug regimen is determined by indication, intended clinical route of administration, considerations for systemic exposure and characterization of toxicity.…”